Ohr Pharmaceutical Reports Fiscal Third Quarter 2015 Financial and Business Results
August 06, 2015 16:01 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Aug. 6, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today reported results for its third fiscal quarter ended June 30,...
Ohr Pharmaceutical Promotes Jason S. Slakter, MD to Chief Executive Officer
August 05, 2015 08:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Aug. 5, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company announced today that Jason S. Slakter, MD, has been appointed Chief...
Ohr Pharmaceutical to Report Third Quarter 2015 Financial and Business Results on Thursday, August 6
July 30, 2015 08:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, July 30, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that it will report financial results for the...
Ohr Pharmaceutical Announces Positive Results of a Phase II Clinical Study for OHR-102 in Retinal Vein Occlusion
July 13, 2015 07:30 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, July 13, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced positive final results from a Phase II...
Ohr Pharmaceutical Reports Fiscal Second Quarter 2015 Financial and Business Results
May 11, 2015 16:01 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, May 11, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today reported results for its second fiscal quarter ended March...
Ohr Pharmaceutical to Report Second Quarter 2015 Financial and Business Results on Monday, May 11
May 11, 2015 08:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, May 11, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that it will report financial results for the...
Ohr Pharmaceutical Presents Data From OHR-102 Phase II IMPACT Study in Wet-AMD at ARVO Conference
May 07, 2015 07:00 ET
|
Ohr Pharmaceutical, Inc.
Visual Acuity Benefits Demonstrated in Classic CNV Containing Lesions
Data Support a Phase III Development Program in an Optimized Wet-AMD Patient Population
NEW YORK, May 7, 2015 (GLOBE...
Ohr Pharmaceutical to Present at the 2015 Association for Research in Vision and Ophthalmology (ARVO) Conference in Denver, CO
April 30, 2015 08:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, April 30, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, announced today the details of two podium presentations at the...
Ohr Pharmaceutical Announces Final Topline Data From OHR-102 Phase II IMPACT Study in Wet-AMD
March 27, 2015 07:00 ET
|
Ohr Pharmaceutical, Inc.
Positive Visual Acuity Benefit in Classic Containing CNV Using OHR-102 Combination Therapy
Conference Call to Discuss Results at 8:00 AM EDT Today
NEW YORK, March 27, 2015 (GLOBE NEWSWIRE) --...
Ohr Pharmaceutical to Present at the 35th Annual Cowen & Company Health Care Conference
March 03, 2015 08:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, March 3, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Dr. Irach Taraporewala, Chief Executive...